TRMT61B

Across TCGA pan-cancer cohorts, TRMT61B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TRMT61B data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TRMT61B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRMT61B expression acts as an unfavorable survival marker.

LIHC, HNSC, and GBM are the cancer types where TRMT61B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.105	0.786	<.001	33	view →
HNSC	DFS	Median	All	0.186	0.605	.003	27	view →
GBM	OS	Median	All	0.070	0.416	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TRMT61B–LIHC (OS)

Open the LIHC breakdown →